+

WO2013033209A1 - Copolymères poly(hydroxy alkanoate) - Google Patents

Copolymères poly(hydroxy alkanoate) Download PDF

Info

Publication number
WO2013033209A1
WO2013033209A1 PCT/US2012/052857 US2012052857W WO2013033209A1 WO 2013033209 A1 WO2013033209 A1 WO 2013033209A1 US 2012052857 W US2012052857 W US 2012052857W WO 2013033209 A1 WO2013033209 A1 WO 2013033209A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
polymer
composition
hydroxy
hydroxypropionate
Prior art date
Application number
PCT/US2012/052857
Other languages
English (en)
Inventor
Scott D. Allen
Geoffrey W. Coates
Original Assignee
Novomer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomer, Inc. filed Critical Novomer, Inc.
Publication of WO2013033209A1 publication Critical patent/WO2013033209A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids

Definitions

  • the invention pertains to the field of poly(hydroxyalkanoate) polymers. More particularly, the invention pertains to poly(hydroxyalkanoate) co-polymers of hydroxy alkanoate isomers.
  • Poly- -hydroxybutyrate is a biodegradable, biocompatible, thermoplastic made by microorganisms.
  • PHB Poly- -hydroxybutyrate
  • Microbial synthesis of PHB, specifically R-PHB, through fermentation is known in the art.
  • Takao et al. Japanese Patent Publication No. 60-251889 A2, entitled “Preparation of Poly ( ⁇ -Hydroxybutyric Acid)", published December 12, 1985, incorporated herein by reference
  • Microbial synthesis of PHB is capable of producing R-PHB with 100% optical purity, but this polymer is crystalline, brittle, and difficult to process.
  • PHBV poly(3-hydroxybutyrate-co-3 -hydroxy valerate)
  • the poly(hydroxy alkanoate) (PHA) product is a co-polymer of two or more hydroxy alkanoates where at least two of the hydroxy alkanoates are regioisomers of each other.
  • the polymer product has a reduced melting point, a reduced crystallinity, and a reduced brittleness in comparison to a pure polymer of either of the two carboxylate isomers.
  • the process for forming a poly(hydroxycarboxylate) product includes forming a mixture of two lactones and forming the polymer by ring opening polymerization of the mixture of lactones.
  • the PHA polymer product includes a plurality of monomer units where at least two of the monomer units are regioisomers of each other.
  • the invention includes methods for forming a poly(hydroxy alkanoate) polymer product from a lactone mixture including a plurality of lactones, at least two of which are regioisomers of each other.
  • the lactone mixtures are made by physically mixing portions of two lactones while in other embodiments, the mixtures of lactones are formed directly by one or more chemical reactions. In certain embodiments, the lactone mixtures are formed directly by carbonylation of epoxide substrates.
  • Fig. 1 shows the 1H nuclear magnetic resonance spectrum of a sample of polymer P4 according to the present invention: the small doublet at 1.18ppm indicates the presence of 2-methyl 3 -hydroxy propionate monomer in the polymer.
  • Fig. 2 shows the l H nuclear magnetic resonance spectrum of prior art poly(hydroxyl butyrate), no doublet at 1.18 ppm is present.
  • Fig. 3 shows the thermal thermogravimetric analysis data indicating the thermal
  • Fig. 4 shows the digital scanning calorimetry profile of the sample from Fig. 1.
  • Certain compounds of the present invention can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers.
  • inventive compounds and compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers.
  • the compounds of the invention are enantiopure compounds. In certain other embodiments, mixtures of enantiomers or diastereomers are provided.
  • certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated.
  • the invention additionally encompasses the compounds as individual isomers substantially free of other isomers and alternatively, as mixtures of various isomers, e.g., racemic mixtures of enantiomers.
  • this invention also encompasses pharmaceutically acceptable derivatives of these compounds and
  • compositions comprising one or more compounds.
  • isomers includes any and all geometric isomers and stereoisomers.
  • “isomers” include cis- and trans-isomers, E- and Z- isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
  • an stereoisomer may, in some embodiments, be provided substantially free of one or more corresponding stereoisomers, and may also be referred to as
  • a particular enantiomer may, in some embodiments be provided substantially free of the opposite enantiomer, and may also be referred to as "optically enriched.”
  • “Optically enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer.
  • Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses.
  • HPLC high pressure liquid chromatography
  • Jacques, et al Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al, Tetrahedron 33 :2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds
  • regioisomer and derivatives of the term such as “regioisomers”, and “regioisomeric” refer to compounds having the same core structure, but differing in the atom of the core structure on which a substituent resides.
  • regioisomeric lactones have the same lactone ring but have substituents on different carbon atoms of the rings.
  • regioisomeric does not place any limitation on the stereochemistry of the compounds being referred to.
  • one or more regioisomeric compounds may be racemic or enantioenriched, and if enantio enriched, the relative stereochemistry of the regioisomers may be the same or different. In some cases one regioisomer may be racemic, while another regioismer may be enantioenriched.
  • halo and “halogen” as used herein refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -CI), bromine (bromo, -Br), and iodine (iodo, -I).
  • aliphatic or "aliphatic group”, as used herein, denotes a hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic (including fused, bridging, and spiro-fused polycyclic) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-30 carbon atoms. In certain embodiments, aliphatic groups contain 1-12 carbon atoms. In certain embodiments, aliphatic groups contain 1-8 carbon atoms. In certain embodiments, aliphatic groups contain 1-6 carbon atoms.
  • aliphatic groups contain 1-5 carbon atoms, in some embodiments, aliphatic groups contain 1 ⁇ 1 carbon atoms, in yet other embodiments aliphatic groups contain 1-3 carbon atoms, and in yet other embodiments aliphatic groups contain 1-2 carbon atoms.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • the term "unsaturated", as used herein, means that a moiety has one or more double or triple bonds.
  • cycloaliphatic used alone or as part of a larger moiety, refer to a saturated or partially unsaturated cyclic aliphatic monocyclic, bicyclic or polycyclic ring systems, as described herein, having from 3 to 12 members, wherein the aliphatic ring system is optionally substituted as defined above and described herein.
  • Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, adamantyl, norbornyl, and cyclooctadienyl.
  • the cycloalkyl has 3-6 carbons.
  • cycloaliphatic also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.
  • alkyl refers to saturated, straight- or branched-chain hydrocarbon radicals derived from an aliphatic moiety containing between one and six carbon atoms by removal of a single hydrogen atom. Unless otherwise specified, alkyl groups contain 1-12 carbon atoms. In certain embodiments, alkyl groups contain 1-8 carbon atoms. In certain embodiments, alkyl groups contain 1-6 carbon atoms. In some embodiments, alkyl groups contain 1-5 carbon atoms, in some embodiments, alkyl groups contain 1-4 carbon atoms, in yet other embodiments alkyl groups contain 1-3 carbon atoms, and in yet other embodiments alkyl groups contain 1-2 carbon atoms.
  • alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec- hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like.
  • alkenyl denotes a monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Unless otherwise specified, alkenyl groups contain 2-12 carbon atoms. In certain embodiments, alkenyl groups contain 2-8 carbon atoms. In certain embodiments, alkenyl groups contain 2-6 carbon atoms. In some embodiments, alkenyl groups contain 2-5 carbon atoms, in some embodiments, alkenyl groups contain 2- ⁇ carbon atoms, in yet other embodiments alkenyl groups contain 2-3 carbon atoms, and in yet other embodiments alkenyl groups contain 2 carbon atoms. Alkenyl groups include, for example, ethenyl, propenyl, butenyl, l-methyl-2- buten-l-yl, and the like.
  • alkynyl refers to a monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Unless otherwise specified, alkynyl groups contain 2-12 carbon atoms. In certain embodiments, alkynyl groups contain 2-8 carbon atoms. In certain embodiments, alkynyl groups contain 2-6 carbon atoms.
  • alkynyl groups contain 2-5 carbon atoms, in some embodiments, alkynyl groups contain 2- ⁇ carbon atoms, in yet other embodiments alkynyl groups contain 2-3 carbon atoms, and in yet other embodiments alkynyl groups contain 2 carbon atoms.
  • alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic and poly cyclic ring systems having a total of five to 20 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to twelve ring members.
  • aryl may be used interchangeably with the term “aryl ring”.
  • “aryl” refers to an aromatic ring system which includes, but is not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more additional rings, such as benzofuranyl, indanyl, phthalimidyl, naphthimidyl, phenantriidinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and “heteroar-”, used alone or as part of a larger moiety e.g., “heteroaralkyl”, or “heteroaralkoxy” refer to groups having 5 to 14 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, benzofuranyl and pteridinyl.
  • heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one.
  • a heteroaryl group may be mono- or bicyclic.
  • the term “heteroaryl” may be used interchangeably with the terms "heteroaryl ring"
  • heteroaryl group or “heteroaromatic”, any of which terms include rings that are optionally substituted.
  • heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • heterocycle As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-14-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), ⁇ (as in pyrrolidinyl), or 3 ⁇ 4fR (as in N-substituted pyrrolidinyl).
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl,
  • pyrrolidonyl piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
  • heterocycle refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
  • partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • compounds of the invention may contain "optionally substituted” moieties.
  • substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
  • an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • each R° may be substituted as defined below and is independently hydrogen, Ci_s aliphatic, -CH 2 Ph, - 0(CH 2 )o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having C heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their
  • Suitable monovalent substituents on R° are independently halogen, -(CH 2 y 2 R e , -(haloR*), -(CH 2 y 2 OH, -(CH 2 y 2 OR e , -(CH 2 y 2 CH(OR') 2 ; -
  • alkylene)C(0)OR or -SSR* wherein each R' is unsubstituted or where preceded by "halo” is substituted only with one or more halogens, and is independently selected from Ci ⁇ aliphatic, -CH 2 Ph, -0(CH 2 )o_iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0M heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR 2)2- 3 0-, wherein each independent occurrence of R is selected from hydrogen, Ci_6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on the aliphatic group of R * include halogen, -R", -(haloR"), -OH, -OR", -O(haloR'), -CN, -C(0)OH, -C(0)OR e , -NH 2 , -NHR", -NR' 2 , or -N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_4 aliphatic, -CH 2 Ph, -0(CH 2 )o iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0 ⁇ 1 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(0)R ⁇ , -C(0)OR ⁇ , -C(0)C(0)R ⁇ , -C(0)CH 2 C(0)R ⁇ , - S(0) 2 R ⁇ , -S(0) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C( H)NR ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, Ci_6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0 ⁇ 1 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(s
  • Suitable substituents on the aliphatic group of R ⁇ are independently halogen, -R", -(haloR*), -OH, -OR", -O(haloR'), -CN, -C(0)OH, -C(0)OR e , -NH 2 , -NHR", -NR' 2 , or -NO2, wherein each R' is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_4 aliphatic, -CH 2 Ph, -0(CH 2 )o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0 ⁇ 1 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • tautomer includes two or more interconvertable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa).
  • the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
  • Exemplary tautomerizations include keto-to-enol; amide-to-imide; lactam-to-lactim; enamine-to-imine; and enamine-to-(a different) enamine tautomerizations.
  • R 1 and R 1 are independently selected from the group consisting of: -H, Ci to C12 alkyl; C 2 to C 12 alkenyl; C 2 to C 12 alkynyl; -C(R 13 ) z H (3 - z) ; -(CH ⁇ R 14 ; and -(CH 2 ) r Z-R 14 ,
  • R 2 , R 2 R 3 , and R 3' are independently selected from the group consisting of:
  • Ci-Ci 2 alkyl a) Ci-Ci 2 alkyl; b) C 2 -Ci 2 alkenyl; c) C 2 -Ci 2 alkynyl; d) Cs to Ci 2 carbocycle; e) C 3 to C heterocycle; f) -( ⁇ 2 ) ⁇ 14; g) R 20 ; and
  • each of (i) through (v) may optionally be further substituted with one or more R 20 groups; and where R 2 and R 2 , and R 3 and R 3 may optionally be taken together with the carbon atoms to which they are attached to form one or more rings which may in turn be substituted with one or more R 20 groups; and
  • R 4 is selected from the group consisting of:
  • R c at each occurrence is independently selected from the group consisting of: a) C1-C12 alkyl; b) C 2 -C 12 alkenyl, c) C 2 -C 12 alkynyl;
  • R d at each occurrence is independently selected from the group consisting of: a) -H; b) Ci-Ci 2 alkyl; c) C 2 -Ci 2 alkenyl, d) C 2 -Ci 2 alkynyl; e) halogen; f) -OR 10 ; g) -OC(0)R 13 ; h) -OC(0)OR 13 ; i) -OC(0)NR n R 12 ; j) -CN; k) -CNO; 1) -C(0)R 13 ; m) -C(R 13 ) z H (3 - z) ; n) -C(0)OR 13 ;
  • R at each occurrence is independently selected from the group consisting of: a) -H; b) halogen; c) -OR 10 ; d) -OC(0)R 13 ; e) -OC(0)OR 13 ;
  • R 10 at each occurrence is independently selected from the group consisting of: a) -C(R 13 ) Z H(3- Z) ; b) d-C 12 alkyl; c) C 2 to C 12 alkenyl; d) C 2 to C 12 alkynyl; e) C3 to C 12 carbocycle; f) C3 to C 12 heterocycle, g) -S(0) 2 R 13 ; h) -Si(R 15 ) 3 ; i) -H; and j) a hydroxyl protecting group,
  • R 11 and R 12 at each occurrence are independently selected from the group consisting of: a) -H; b) Ci to C 12 alkyl; c) C 2 to C 12 alkenyl;
  • R 13 at each occurrence is independently selected from the group consisting of: a) -H; b) Ci-Ci 2 alkyl; c) C 2 to C 12 alkenyl; d) C 2 to C 12 alkynyl; e) C3 to C 12 carbocycle; f) C3 to C 12 heterocycle,
  • R 14 at each occurrence is independently selected from the group consisting of: a) halogen; b) -OR 10 ; c) -OC(0)R 13 ; d) -OC(0)OR 13 ; e)-OC(0)NR u R 12 ; f) -CN; g) -CNO; h) -C(R 13 ) z H (3 - z) ; i) -C(0)R 13 ; j) -C(0)OR 13 ; k) -C(0)NR n R 12 ; m) -NR n C(0)R 13 ;
  • R 15 at each occurrence is independently selected from the group consisting of: Ci-Ce alkyl, C2 to Ce alkenyl, C2 to Ce alkynyl, and C3 to C 12 substituted or unsubstituted carbocycle,
  • R 16 at each occurrence is independently selected from the group consisting of: b) C1-C12 alkyl; c) C 2 to C 12 alkenyl; d) C 2 to C 12 alkynyl; C 3 to
  • a is 1, 2, 3, or 4
  • k is an integer from 1 to 8 inclusive
  • m is an integer from 1 to 8 inclusive
  • x is 0, 1, or 2
  • z is 1, 2, or 3.
  • the present invention encompasses poly(hydroxyl alkanoate) compositions (PHAs) that are copolymers of at least one 3 -substituted-3 - hydroxy propionate and at least one 2-substituted-3 -hydroxy propionate.
  • PHAs poly(hydroxyl alkanoate) compositions
  • the 3 -substituted-3 -hydroxy propionate and the 2-substituted-3 -hydroxy propionate have different substituents (i.e. the group at the 3-position of the 3-substituted- 3 -hydroxy propionate is not identical to the group at the 2-position of the 2-substituted-3- hydroxy propionate).
  • the 3 -substituted-3 -hydroxy propionate and the 2-substituted-3 -hydroxy propionate have identical substituents (i.e. the group at the 3-position of the 3 -substituted-3 -hydroxy propionate is the same as the group at the 2-position of the 2-substituted-3-hydroxy propionate).
  • one monomer unit is a 3-substituted-3-hydroxypropionate (Ml)
  • another monomer is a 2-substituted-3-hydroxypropionate (M2) where the substituent R s on each monomer is the same.
  • one monomer unit Ml has the structure:
  • each R s is independently selected from the group consisting of: optionally substituted Ci to C2 0 aliphatic; optionally substituted Ci to C2 0 heteroaliphatic; optionally substituted C3 to C12 carbocyclic; and C3 to C12 optionally substituted heterocyclic.
  • the molar ratio of 3-substituted-3-hydroxypropionate (Ml) to 2-substituted-3-hydroxypropionate (M2) in the polymer is greater than 1 : 1. In one embodiment, the molar ratio ofMl to M2 is greater than 5: 1. In another embodiment, the molar ratio ofMl to M2 is greater than 10: 1. In another embodiment, the molar ratio of Ml to M2 is greater than 20: 1. In another embodiment, the molar ratio ofMl to M2 is greater than 50: 1. In another embodiment, the molar ratio ofMl to M2 is greater than 100: 1. In another embodiment, the molar ratio ofMl to M2 is greater than 1000: 1.
  • monomers with the structure M2 comprise 5 to 20% of the polymer, and monomers having structure Ml comprise 80 to 95% of the polymer. In other embodiments, monomers having structure M2 comprise 1 to 5% of the polymer and monomers having structure Ml comprise 95 to 99% of the polymer. In other embodiments, monomers having structure M2 comprise 0.01 to 1% of the polymer and monomers having structure Ml comprise 99 to 99.99% of the polymer.
  • the stereochemistry of the 3-substituted-3- hydroxypropionate is the opposite of the stereochemistry of the 2-substituted-3- hydroxypropionate. In other embodiments, the stereochemistry of the 3 -substituted-3 - hydroxypropionate is the same as the stereochemistry of the 2-substituted-3- hydroxypropionate. In certain embodiments, one of the monomers is enantio-enriched, and another monomer is racemic. In one embodiment, the 3 -substituted-3 -hydroxypropionate monomer is enantioenriched and the 2 -substituted-3 -hydroxypropionate monomer is not enantioenriched.
  • polymers of the present invention encompass random copolymers, tapered copolymers, or block copolymers incorporating at least one monomer from Table la, and at least one monomer from Table lb.
  • polymers of the present invention encompass random copolymers, tapered copolymers, or block copolymers incorporating at least one monomer from Table 1 a, and at least one monomer from Table lb where the substituent on the monomer from Table la and the substituent on the monomer from Table lb are the same.
  • one monomer unit in the polymer has the structure M3:
  • M3 and another monomer unit in the polymer has the structure M4:
  • R s is as defined above.
  • one monomer unit in the polymer has the structure M5:
  • one monomer unit in the polymer has the structure M7:
  • the present invention encompasses polymers having structure PI :
  • the invention includes methods for forming a poly(hydroxy alkanoate) polymer product from a lactone mixture including a plurality of lactones, where the mixture contains at least one 2-substituted propiolactone and at least one 3-substituted propiolactone.
  • the 2-substituted propiolactone and the 3- substituted propiolactone have different substituents.
  • at least one 2- substituted propiolactone and at least one 3-substituted propiolactone have the same substituent.
  • the method includes the steps of forming a lactone mixture including a first lactone LI and a second lactone L2: , where R s is as defined above,
  • provided methods include the steps of forming a lactone mixture including a first lactone L3 and a second lactone L4: , where R s is as defined above,
  • provided methods include the steps of forming a lactone mixture including a first lactone L5 and a second lactone L6:
  • provided methods include the steps of forming a mixture including (R)- -butyrolactone L7 and a (R)-2-methyl-propiolactone L8:
  • provided methods include the steps of forming a lactone utyrolactone L9 and a rac-2-methyl-propiolactone L10:
  • provided methods include the steps of forming a lactone mixture including rac-3 -substituted propiolactone Lll and a rac-2-substituted- propiolactone L12:
  • the polymerizations shown in Scheme 6 may occur such that both Lll and L12 are stereos electively polymerized. In that case, the reaction would yield polymer along with enantioenriched Lll and L12. In other cases, the catalyst may act such that only one lactone Lll or L12 is enantioselectively polymerized, while the other lactone is incorporated without enantioselectivity.
  • provided methods include the steps of forming a lactone mixture including rac-3 -substituted propiolactone Lll and a rac-2-substituted- propiolactone L12: , where R s is as defined above,
  • provided methods include the steps of forming a mixture including (R)-3-ethyl-propiolactone L13 and a (R)-2-ethyl-propiolactone L14:
  • provided methods include the steps of forming a mixture including ⁇ -butyrolactone L15, 2-methyl-propiolactone L16, and 3-ethyl-propiolactone
  • provided methods include the steps of forming a mixture including ⁇ -butyrolactone L15, 2-methyl-propiolactone L16, 3-ethyl-propiolactone L17, and 2-ethyl-propiolactone L18:
  • the polymers PI through P9 are random copolymers. In other embodiments, the polymers PI through P5 are tapered copolymers.
  • Catalysts suitable for the ring-opening polymerization step of the methods disclosed herein are disclosed, for example, in: Journal of the American Chemical Society (2002), 124(51), 15239-15248 Macromolecules. vol. 24, No. 20, pp. 5732-5733, Journal of Polymer Science. Part A-l, vol. 9, No. 10, pp. 2775-2787; Inoue, S., Y. Tomoi, T. Tsuruta & J. Furukawa; Macromolecules. vol. 26, No. 20, pp. 5533-5534;
  • the lactone mixtures are made by physically mixing portions of two or more lactones.
  • the lactones that are thus mixed may be obtained by any methods known in the art. Suitable methods for making lactones suitable for the present invention are described, for example, in Catalytic Asymmetric Synthesis of ⁇ -Lactones and Application to the Total Synthesis of (-)-Pironetin (Xiaoqiang Shen, 2007 Ph.D. dissertation, University of Pittsburgh) the entirety of which is hereby incorporated herein by reference.
  • methods of the present invention include the steps of mixing a plurality of lactones, at least two of which are regioisomers of each other, and contacting the mixture with a polymerization catalyst to form a PHA polymer incorporating both of the regioisomeric lactones.
  • the methods of the present invention include the step of combining lactones LI and L2 to form a mixture, and treating the mixture with a polymerization catalyst C2 to form a polymer PI, as shown in Scheme 10.
  • the mixtures of lactones are formed by carbonylation of epoxide substrates. Suitable conditions for such carbonylations may be found, for example, in US Patent Application Serial No. US 2005-0014977 and in US Patent Nos. 6,852,865 and 7,569,709, the entirety of each of which are incorporated herein by reference.
  • methods of the present invention include the steps of contacting a mixture containing one or more epoxides with a carbonylation catalyst CI to produce a mixture of lactone products, at least two of which are regioisomers of each other, and contacting the mixture with a polymerization catalyst to form a PHA polymer incorporating both of the regioisomeric lactones.
  • methods of the present invention include the steps of: a) contacting an epoxide El with carbon monoxide and a carbonylation catalyst CI to provide a mixture of lactones comprising LI and L2, and b) treating the mixture of lactones with a
  • methods of the present invention include one or more additional steps of isolating or purifying the mixture of LI and L2 prior to treating the mixture with the polymerization catalyst.
  • the mixture of products formed by the carbonylation step are treated directly with the polymerization catalyst C2.
  • the carbonylation step and the polymerization step are carried out sequentially on the same reaction mixture.
  • the carbonylation step and the polymerization step are carried out sequentially in the same reaction vessel.
  • the carbonylation step and the polymerization step are carried out concomitantly.
  • mixtures of three or more lactones are produced from mixtures of two or more epoxides.
  • a mixture of two different epoxides El and El' is treated with a carbonylation catalyst CI to produce a mixture of products including at least two products derived from El that are regioisomers of each other (such as LI and L2).
  • the products of such mixtures include one or more carbonylation products such as LI' derived from El'.
  • the carbonylation of El' may also yield a mixture of regioisomers such that the mixture of lactones includes four lactones: two regioisomeric lactones derived from El, plus two regioisomeric lactones derived from
  • R s of the epoxide El is as defined hereinabove.
  • the epoxide El has a structure selected from those in Table 2.
  • the epoxide El employed in the first step is enantioenriched. In other embodiments, the epoxide El employed in the first step is racemic. In certain embodiments of the present invention, the epoxide El is racemic, and the carbonylation catalyst CI is enantioselective such that the one or both of the lactones LI and L2 resulting from the carbonylation step are enantioenriched.
  • the carbonylation catalyst CI comprises a Lewis acid in combination with a carbonyl complex of a transition metal.
  • Lewis acid refers to any electrophilic species that is capable of accepting an electron pair and that is not a Bronsted-Lowry acid.
  • the Lewis acid portion of the catalyst includes an element from groups 3 through 14 of the periodic table or contains a lanthanide metal.
  • Lewis acids useful for the invention may either be neutral (e.g.
  • M is a metal
  • each L is a ligand
  • x is an integer from 1 to 6 inclusive
  • z is 0, 1, 2, or 3, and where, if more than one L is present, each L may be the same or different.
  • M is a transition metal, a group 13 or 14 metal, or a lanthanide. More preferably, M is a transition metal or a group 13 metal.
  • M is aluminum, chromium, indium or gallium, with aluminum and chromium being particularly preferred.
  • a range of ligands (L) can be present in the metallo Lewis acid component of the catalyst CI.
  • a preferred class of ligands includes dianionic tetradentate ligands.
  • Suitable ligands for the metallo Lewis acid component of the catalyst CI include, but are not limited to: porphyrin derivatives 1, salen derivatives 2,
  • tmtaa dibenzotetramethyltetraaza[14]annulene (tmtaa) derivatives 3, phthalocyaninate derivatives 4, and derivatives of the Trost ligand 5, with porphyrin, salen, and tmtaa derivatives being particularly preferred ligands.
  • a mixture of more than one Lewis acid component can be present in the catalyst CI.
  • the transition metal carbonyl complex included in the carbonylation catalyst CI may be neutral or anionic.
  • the metal carbonyl complex is anionic.
  • Preferred anionic metal carbonyl complexes include monoanionic carbonyl complexes of metals from groups 5, 7 or 9 of the periodic table and dianionic carbonyl complexes of metals from groups 4 or 8 of the periodic table. More preferably, the metal carbonyl complex contains a metal from groups 7 or 9 of the periodic table, more preferably cobalt, manganese or rhodium.
  • suitable anionic metal carbonyl complexes include, but are not limited to: [Co(CO) 4 ] ⁇ and [Mn(CO) 5 ] ⁇ with [Co(CO) 4 ] " being particularly preferred. In some cases, a mixture of two or more transition metal carbonyl complexes may be present in the catalyst.
  • the polymerization catalyst C2 there are numerous catalysts known to promote the ring-opening polymerization of lactones such as LI and L2. Any such known catalysts can be employed in methods of the present invention. Because some catalysts are more sensitive to parameters such as substrate steric hindrance than others, the choice of the catalyst C2 can affect the proportions of LI and L2 incorporated into the polymer formed. The ratio of incorporation of LI to L2 in the polymer formed by a particular catalyst can be determined by routine analytical techniques such as 13 C NMR spectroscopy. Modifications such as selection of the different catalysts C2 to optimize the polymerization of a particular mixture of lactones are encompassed by the present invention.
  • Catalysts C2 suitable for the polymerization step of the present invention are disclosed, for example, in: Journal of the American Chemical Society (2002), 124(51), 15239-15248 Macromolecules. vol. 24, No. 20, pp. 5732-5733, Journal of Polvmer Science. Part A-l, vol. 9, No. 10, pp. 2775-2787; Inoue, S., Y. Tomoi, T. Tsuruta & J. Furukawa; Macromolecules. vol. 26, No. 20, pp. 5533-5534; Macromolecules. vol. 23, No. 13, pp. 3206-3212; Polvmer Preprints (1999), 40(1), 508-509; Macromolecules. vol. 21, No.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des compositions de poly(hydroxycarboxylate) ayant un copolymère de deux isomères de carboxylate. Le produit polymère présente un point de fusion réduite, une cristallinité réduite, ainsi qu'une friabilité réduit comparée à un polymère pur de l'un ou de l'autre des deux isomères de carboxylate. Le procédé de formation d'un produit poly(hydroxycarboxylate) consiste à former un mélange d'au moins deux lactones et à former le polymère par polymérisation par ouverture de cycle du mélange.
PCT/US2012/052857 2011-08-29 2012-08-29 Copolymères poly(hydroxy alkanoate) WO2013033209A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528307P 2011-08-29 2011-08-29
US61/528,307 2011-08-29

Publications (1)

Publication Number Publication Date
WO2013033209A1 true WO2013033209A1 (fr) 2013-03-07

Family

ID=47756829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052857 WO2013033209A1 (fr) 2011-08-29 2012-08-29 Copolymères poly(hydroxy alkanoate)

Country Status (1)

Country Link
WO (1) WO2013033209A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068803A2 (fr) * 2000-03-02 2001-09-20 Maxygen, Inc. Enzymes, voies et organismes pour la fabrication d'un monomere polymerisable par un bioprocessus cellulaire integral
US7244442B2 (en) * 1997-05-12 2007-07-17 Metabolix, Inc. Method for making devices using polyhydroxyalkanoate having pyrogen removed
US7781539B2 (en) * 2003-02-21 2010-08-24 Metabolix Inc. PHA blends

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244442B2 (en) * 1997-05-12 2007-07-17 Metabolix, Inc. Method for making devices using polyhydroxyalkanoate having pyrogen removed
WO2001068803A2 (fr) * 2000-03-02 2001-09-20 Maxygen, Inc. Enzymes, voies et organismes pour la fabrication d'un monomere polymerisable par un bioprocessus cellulaire integral
US7781539B2 (en) * 2003-02-21 2010-08-24 Metabolix Inc. PHA blends

Similar Documents

Publication Publication Date Title
EP2734532B1 (fr) Complexes métalliques
EP2707353B1 (fr) Catalyseurs de carbonylation et procédé
EP3171976B1 (fr) Synthèse de complexes métalliques et leurs utilisations
US9156803B2 (en) Succinic anhydride from ethylene oxide
CN107428656B (zh) 连续羰基化方法
US20200239627A1 (en) Process and system for production of polypropiolactone
EP2888271B1 (fr) Complexes métalliques
WO2014004858A1 (fr) Catalyseurs et procédés de fabrication de polyester
AU2015229061A1 (en) Catalysts for epoxide carbonylation
WO2018200471A1 (fr) Systèmes et procédés de thermolyse de polylactones pour produire des acides organiques
EP2285864A1 (fr) Polymères d oxyde d éthylène et de dioxyde de carbone
EP2867189A2 (fr) Procédé de production d'acrylate
WO2011123558A1 (fr) Synthèse de complexes métalliques
WO2013033209A1 (fr) Copolymères poly(hydroxy alkanoate)
WO2013138243A1 (fr) Composés bifonctionnels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12828472

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12828472

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载